Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Lymphodepleting chemotherapy in order to safely improve the expansion of HER2-CAR T cells in patients with advanced sarcomas

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 15.04.19
Views: 438

Prof Shoba Navai - Baylor College of Medicine, Houston, USA

Prof Shoba Navai speaks to ecancer at the 2019 American Association for Cancer Research (AACR) meeting about results from a study looking at lymphodepleting chemotherapy in order to safely improve the expansion of HER2-CAR T cells in patients with advanced sarcomas.

She explains that the study succeeded in safely doing this with very limited toxicities seen and no cardiac toxicities which can be seen in other HER-2 directed therapies.

Prof Navai reports that the addition of lymphodepletion did help improve CAR T cell expansion in the blood and that there are early signs that endogenous immunity may be engaged when administrating the CAR T cells.

Read more about this research here.

Related videos

18.06.19

no rating
Cancer care in Latin America

follow us

Core Surgical Training


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation